Functional analyses of two novel LRRK2 pathogenic variants in familial Parkinson's disease
Ilda CokuiD, Eugénie MuteziD, Sabiha EddarkaouiiD, Sébastien Carrier, Antoine MarchandiD, Claire Deldycke, Liesel Mary GoveasiD, Guillaume BailleiD, Mélissa TiriD, Romain MagneziD, Xavier ThuruiD, Gaëlle Vermeersch, Wim VandenbergheiD, Luc BuéeiD, Luc DefebvreiD, Bernard SablonnièreiD, Marie‐Christine Chartier‐HarliniD, Jean‐Marc TaymansiD, Vincent HuiniD
Abstract
BackgroundPathogenic variants in the LRRK2 gene are a common monogenic cause of Parkinsons disease. However, only seven variants have been confirmed to be pathogenic. ObjectivesWe identified two novel LRRK2 variants (H230R and A1440P) and performed functional testing. MethodsWe transiently expressed wildtype, the two new variants, or two known pathogenic mutants (G2019S and R1441G), in HEK-293T cells, with or without LRRK2 kinase inhibitor treatment. We characterized the phosphorylation and kinase activity of the mutants by western blotting. Thermal shift assays were performed to determine the folding and stability of the LRRK2 proteins. ResultsThe two variants were found in two large families and segregate with the disease. They display altered LRRK2 phosphorylation and kinase activity. ConclusionsWe identified two novel LRRK2 variants which segregate with the disease. The results of functional testing lead us to propose these two variants as novel causative mutations for familial Parkinsons disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 8
- FWCI
- 0.92
- Field percentile
- top 26%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- LRRK2 exonic variants associated with Parkinson’s disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73
Kenneth V. Christensen, Morten Hentzer, … Garrick P. Smith·bioRxiv·Oct 22, 2018
- Parkinson's disease-associated LRRK2 risk variant, G2385R, enhances Rab substrate phosphorylation and impairs neuronal integrity
An Phu Tran Nguyen, Roger Moser, … Darren J. Moore·Human Molecular GeneticsPeer-reviewed·Jan 1, 2026
- Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson disease
Mie Rizig, Oluwadamilola Omolara Ojo, … Njideka Ulunma Okubadejo·Neurobiology of AgingPeer-reviewed·Oct 1, 2020
- Impact of 100 LRRK2 variants linked to Parkinsons Disease on kinase activity and microtubule binding
Alexia F. Kalogeropulou, Elena Purlyte, … Dario R. Alessi·Biochemical JournalPeer-reviewed·Aug 11, 2022
- MDSGene update and expansion: Clinical and genetic spectrum of LRRK2 variants in Parkinson's disease
Clara Krüger, Shen‐Yang Lim, … Katja Lohmann·medRxiv·Dec 10, 2024
- Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinsons disease
Nicola Whiffin, Irina M. Armean, … Matthew B. Harms·Nature MedicinePeer-reviewed·May 27, 2020